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Abstract 
Great care is generally taken in epidemiologic studies to ensure the internal validity 
of causal effect estimates; however, the external validity of effect estimates, has 
received considerably less attention. The causal effect in a given target population is 
the average of heterogeneous subgroup effects, weighted according to the 
prevalence of the subgroups in the target population. When the study sample is not 
a random sample of the target population, the sample average treatment effect, even 
if internally valid, cannot be expected to equal the average treatment effect in the 
target population. There are several categories of choices for the target population. 
The study sample may be a census of the target population; the population from 
which the study sample is a random sample or from which the study sample is not a 
random sample; or some other population of which, the study sample is not a subset 
of the target population. The identification conditions sufficient for external validity 
closely parallel the identification conditions for internal validity, namely: 
conditional exchangeability; positivity; similar distributions of the versions of; 
similar patterns of interference; no measurement error; and correct model 
specification. The value of an effect estimate for planning purposes and decision 
making will depend on the degree of departure from both internal and external 
validity. If the study sample is not a random sample of the target population, direct 
standardization (the g-formula or transport formula) or inverse probability 
weighting can be used to estimate a causal effect in the target population.  
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Epidemiology as a discipline is distinguished by its efforts to identify causes 
of disease for the purpose of intervening to improve public health. Great care is 
generally taken in epidemiologic studies to ensure the internal validity of causal 
effect estimates,1 including the application of methods to minimize the potential for 
bias due to measurement error, confounding, selection (specifically, due to missing 
data, including censoring and truncation), and model misspecification. However, the 
external validity of effect estimates, has received considerably less attention. For the 
purposes of this discussion, we use the term external validity to refer to the 
potential for an internally valid treatment (or exposure or intervention) effect 
measured in a study sample to differ from the treatment effect that would have been 
estimated in the population of interest2 (henceforth, the target population). External 
validity encompasses generalizability and transportability, which we distinguish 
below. We advance the discussion of external validity herein using a potential 
outcomes framework. We enumerate a set of identification assumptions sufficient to 
estimate an externally valid effect, and note the parallel between these and the 
identification assumptions sufficient to estimate an internally valid effect. Finally, 
we illustrate some issues regarding generalizability with a simple example and 
discuss practical considerations for addressing generalizability in epidemiological 
study design. 
 
Definitions and causal framework 
A well-defined causal question states the outcome(s) of interest, denoted by 
𝑌; the treatments of interest, denoted by 𝐴; and the target population, of size 𝑁 
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described by a set of characteristics denoted by W. Here, we assume variables in W 
are discrete, however, all concepts are easily extended to the case of continuous W. 
The causal effect of interest is a contrast (i.e., a difference or ratio) of the 
distribution of potential outcomes, 𝑌(𝑎), in the target population under two 
different interventions, treatments, or policies of interest, for example:  
𝐸𝑇{𝐸[𝑌(𝑎)|W]𝑃𝑇(W)} − 𝐸𝑇{𝐸[𝑌(𝑎
′)|W]𝑃𝑇(W)}                    (1) 
where 𝑌(𝑎) denotes the outcome that a participant would have if he or she received 
treatment 𝑎, and the subscript 𝑇 denotes that the set of characteristics W takes the 
distribution seen in target population. This notation makes it clear that the overall 
causal effect in the target population is the average of effects that are heterogeneous 
according to W, with weights defined by the distribution of W in the target 
population, 𝑃𝑇(W). 𝑃𝑇(W) is often omitted when the causal effect of interest is 
written (i.e. E[𝑌(𝑎)] − E[Y(𝑎′)]) under the implicit assumption that either 1) the 
study sample is a census of the target population; 2) the study sample is a simple 
random sample from the target population, i.e., the distribution of W in the study 
sample, denoted 𝑃𝑠(𝑊), is equal to  𝑃𝑇(W)  in expectation; 3) there is a distinct 
target population, 𝑀, of which the study sample is not a proper subset, for which 
𝑃𝑀(W)  is equal to 𝑃𝑆(W); or 4) the causal effect is homogeneous across all 𝑊 for the 
causal contrast of interest.  
It is helpful to distinguish threats to validity that arise after enumeration of 
the study sample, which we define as threats to internal validity, from threats to 
validity due to eligibility and enrollment of study subjects, which we define as 
threats to external validity. We define an estimator as internally valid when the 
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estimator of association in the study sample is a consistent estimator of the 
treatment effect in the source population from which the study participants are 
randomly sampled (the sample average treatment effect). The distribution of 𝑊 in 
the study sample, 𝑃𝑆(W), may differ from 𝑃𝑇(W) without threatening internal 
validity. We define a causal estimator to be externally valid when the sample 
average treatment effect is a consistent estimator of the average treatment effect in 
the target population (population average treatment effect). An estimate will be 
externally valid under one of the first three scenarios described above, all of which 
result in the distribution of W in the study sample being equal to the distribution of 
W in the target population. 
 
Assumptions 
Given we cannot observe all potential outcomes for subjects in our target 
population or our study sample,3,4 we can rely on a sufficient set of identification 
assumptions under which (with a consistent estimator) an estimate of association 
could be interpreted causally.  
These assumptions are well described in the literature for estimating an 
internally valid causal estimate. They include: 1) the unexposed are a good 
substitute for the experience of the exposed in the absence of exposure and vice 
versa (exchangeability), perhaps conditional on a set of covariates, Z (conditional 
exchangeability); 2) a non-zero probability of exposure within every stratum 
defined by Z (positivity); 3) treatment variation irrelevance or no versions of 
treatment (sometimes referred to as consistency);5-84) no interference or partial 
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interference (or some other restriction on the interference structure);9,10  5) no 
measurement error; and 6) if Z is high dimensional and non-parametric inference is 
unfeasible, correct specification of parametric models.  
The identification conditions sufficient for external validity closely parallel 
the identification conditions for internal validity.18,27 First, we assume that the 
participants included in the sample are exchangeable with members of the target 
population who were not sampled, perhaps conditional on W (conditional 
exchangeability):  
𝑆 ⊥ [𝑌(𝑎), 𝑌(𝑎′)]|W  
where 𝑆 is an indicator of enrollment into the study sample. Enrollment into the 
sample is both under the control of the researcher (in designing a recruitment 
strategy) and under the control of the participants (in deciding whether to provide 
consent to participate). For the purposes of identification of the causal contrast in 
the target population, the set of characteristics, 𝑊, is sufficient if it includes all 
causes of (or proxies for causes of) sampling and the outcome. If the researcher is 
willing to specify a single causal contrast of interest, then the set of characteristics 
W may be restricted to a subset of W that are effect measure modifiers of that 
contrast.2 Second, we assume that, within strata of W, all subjects in the target 
population have some probability of being selected into the sample (𝑆 = 1) 
(positivity):  
0 < Pr(S = 1|W) < 1, for all W, such that 𝑃𝑇(W) > 0 
Third, we assume similar distribution of the versions of treatment in the study 
sample and the target population (of which treatment variation irrelevance is a 
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special case). This may be a strong assumption when the delivery mechanism for 
treatment differs dramatically between the study sample and the target population 
(e.g., treatment given to trial participants may have been accompanied by more 
adherence education and supportive services, as well as Hawthorne effects due to 
trial participation).11 Fourth, we assume similar patterns of interference in the 
target population and the study sample (of which no interference is a special 
case).11-13 Finally, we assume no measurement error for exposure, outcome, and all 
variables W, and correct model specification (if we use a parametric model ).  
 
Defining the target population  
Failure to specify the target population explicitly precludes comparisons 
between the target population and the study sample of patient characteristics 
(exchangeability), details of the implementation of the intervention (treatment 
versions), or the comparison of patterns of interference between the target 
population and the study sample. In failing to make these aspects explicit in study 
design and planning, the generalizability of study results to some unspecified target 
population is nebulous.14-18  
There are several categories of choices for the target population.19 First, the 
study sample may be a census of the target population. This is almost never the case, 
because in nearly all instances, we have done research to inform decisions about a 
population at least somewhat different than that under study.  A second choice for 
the target population may be the population from which the study sample was 
sampled. When the sampling is random, 𝑃𝑆(W) is the same as 𝑃𝑇(W) in expectation 
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and sample average treatment effect equals the population average treatment effect 
in expectation (Figure 1a). When the study sample is not a random sample from the 
target population and 𝑃𝑆(W) differs from 𝑃𝑇(W), the sample average treatment 
effect can be expected to differ from the population average treatment effect (Figure 
1b). A third choice for the target population is some other population that does not 
include the study sample  (Figure 1c). In both of the latter cases (study sample not a 
random sample of the target; external population), additional information is needed 
to estimate the effect of interest in the target population, namely the distribution of 
𝑃𝑇(W).  
A distinction between generalizing results to a target population that 
includes as members those persons included in the study sample (Figures 1a and 
1b) and transporting results to a target population that is non-overlapping with the 
study sample (Figure 1c) has been made previously, but not discussed in depth.20 In 
the former case, a physical probability of sampling can be envisioned;21 in the latter, 
the probability of sampling is not physical.21,22 This should not alarm us; 
transporting results to a target population that is non-overlapping with the study 
sample is simply direct standardization. Graphical criteria can assist in determining 
whether an estimate of effect is directly transportable and if not, can help identify 
the appropriate “transport formula” for estimating an effect for the target 
population.23,24 Despite these distinctions between target populations are 
overlapping or non-overlapping with the study sample, the same set of 
generalizability assumptions described above holds in both scenarios.  
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Example 
 To demonstrate how the sample average treatment differs from the 
population average treatment effect when the study sample is not a random sample 
of the target population, consider the following example. Imagine the target 
population comprises 𝑁 = 50,000 individuals, in whom the prevalence of two 
dichotomous causes of the outcome, 𝑊1 and 𝑊2, is 0.15 and 0.20, respectively. In the 
study sample (𝑛=1,000), as in many trials, participants at greater risk of the 
outcome (𝑊1 = 1 or 𝑊2 = 1) were oversampled, with 𝑃(𝑊1) = 0.5 and 𝑃(𝑊2) = 0.5. 
In both the study sample and in in the target population, the exposure, 𝐴, is 
randomly assigned with probability 0.5. The 1-year risk for the outcome is defined 
by the function: 𝑃(𝑌 = 1) = 0.1073 − 0.05𝐴 + 0.20𝑊1 + 0.20𝑊2 − 0.15𝐴𝑊1𝑊2. The 
data from one realization of a target population and study sample generated under 
these conditions appears in Table 1. 
Given this realization of the data, the estimate of the risk difference due to 𝐴 
in the target population is -5.3%. The estimate of the risk difference due to 𝐴 in the 
study sample is -9.7%.  
The g-formula or inverse probability (IP) of sampling weights can be used to 
use the study sample data to estimate the population average treatment effect. The 
g-formula (equivalent to Bareinboim & Pearl’s “transport formula”)23 and equation 
(1) above is:  
𝑃[𝑌(𝑎)] = ∑ 𝑃[𝑌(𝑎)|𝑊 = 𝑤]𝑃𝑇(𝑊 = 𝑤)
𝑊
 
   
 
10 
Generalizability Definitions 
Which, if we assume consistency and conditional exchangeability given 𝑊, can be 
estimated by:  
𝑃[𝑌 = 1|𝐴 = 𝑎] = ∑ 𝑃[𝑌 = 1|𝐴 = 𝑎, 𝑊 = 𝑤]𝑃𝑇(𝑊 = 𝑤)
𝑊
 
where the quantity 𝑃[𝑌 = 1|𝐴 = 𝑎, 𝑊 = 𝑤] is estimated in the study sample and 
𝑃𝑇(𝑊 = 𝑤) is the probability that 𝑊 = 𝑤 in the target population. The estimate of 
effect in the target population using the non-parametric g-formula was -5.4%.  
Scaled IP of sampling weights were defined:  
𝑃(𝑆 = 1)
𝑃(𝑆 = 1|𝑊1 = 𝑤1 , 𝑊2 = 𝑤2)
 
If the set of covariates, 𝑊, that should be included in calculating IP of sampling 
weights is high dimensional, the denominator of the weights can be modeled 
parametrically. In this example, we used a fully saturated model for the 
denominator of the weights. The IP of sampling weighted estimate of effect in the 
target population based on data from the study sample was -5.4%.  
  
Note that the results from the IP of sampling approach and the g-
formula/transport formula will be equivalent when both are estimated non-
parametrically. In practice, if the dimension of 𝑊 is large and 𝑃(𝑆 = 1) or 𝑃(𝑌 =
1|𝐴 = 𝑎, 𝑊 = 𝑤) is modeled, the two approaches may give different results due to 
different modelling assumptions or model misspecification. Doubly robust 
estimation of the population average treatment effect is also possible.25 
 
Practical considerations for study design 
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The only way to ensure an estimate is directly generalizable (in expectation) 
to a particular target population would be draw the study sample as a random 
sample from that target population as described above.12 However, beyond the 
logistical, financial, and ethical challenges to conducting such a study, in certain 
circumstances, a study sample that is representative of the target population may be 
undesirable.18,26,27 When first exploring the existence of a causal effect, non-random 
sample selection may be purposefully undertaken. For example, an investigator 
might enroll a sample for a trial that has a higher than average risk of disease to 
increase statistical efficiency, or restrict enrollment into an observational study to 
control for an important confounder. Oversampling to avoid sparse numbers of 
patients within subgroups improves precision during confounder control and also 
allows estimation of subgroup effects,18,26 although trials are rarely powered to 
estimate such subgroup effects.   
Epidemiologists are typically primarily concerned with the internal validity 
of effect estimates. However, the value of an effect estimate for planning purposes 
and decision making will depend on the degree of departure from both internal and 
external validity. External validity will be threatened to the degree that 1) the 
prevalence of other causes of the outcome (also versions of treatment, patterns of 
interference) differs in the study sample and the target population, and 2) the 
exposure or intervention causal contrast is modified by those other causes of the 
outcome that differ in the study sample and the target population.2 For example, 
Greenhouse et al., describe a trial of antidepressants in adolescents that pointed to 
an increased risk of suicide, but which excluded participants with the most severe 
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depression who would have experienced the greatest benefits from the therapy.15 In 
this case, while the trial effects were internally valid, the lack of external validity had 
serious implications for policy and removed potentially beneficial treatment options 
from depressed adolescent patients. A second example is, the discrepancies between 
the conclusions about the effects of combined estrogen/progestin menopausal 
hormone replacement therapy (HRT) on coronary heart disease based on the 
Women’s Health Initiative trial and the Nurses’ Health Study can be recast as a 
generalizability problem if we consider that the age- and time-on-exposure stratum 
specific effects of HRT estimated in both studies were similar,28 but the distribution 
of women by age and time-on-exposure in the target population (young women with 
no prior exposure) did not match the distribution of women in the study sample 
from the Nurses’ Health Study (older women with lots of prior exposure). In this 
instance, while internal validity (confounding by some unmeasured factor) was 
initially blamed for the discrepancy, and while generalizability is typically only 
thought of as an issue for clinical trials, the generalizability of this observational 
study undermined policy recommendations based on its results. Such examples 
highlight the importance of balancing study design decisions to maximize both 
internal and external validity.  
If our study sample is not a random sample of the target population, we can 
estimate causal effects in a specified target population using direct standardization 
or inverse probability weighting (a semiparametric extension of direct 
standardization)29 if all predictors of both selection into the study sample and the 
outcome are measured in both the study sample and the target population. This 
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methodological solution would allow us to use a single study sample to calculate 
generalized estimates of effect for multiple different specified target 
populations2,12,13 as long as the distribution of W was available for the target 
population.15,30 
 
Discussion 
Commentaries on the lack of generalizability of randomized trials typically 
implore the reader to evaluate a lengthy check list of potential determinants of 
external validity,16,17,31 or further classify the list into categories to distinguish 
“external validity” from “applicability.”32 We argue that such exercises could be 
more efficient if considered quantitatively, within the potential outcomes 
framework. This approach would quickly narrow the scope of future research 
needed to ascertain the effect estimate of interest because specific threats to the 
external validity of the estimate could be identified and used to guide future study 
design. Furthermore, understanding the mechanism by which differences between 
the sample and the target population influence the generalizability of a sample 
estimate would help identify the most appropriate methods to account for those 
differences. Understanding differences in the distribution of risk factors for the 
outcome has implications for the selection of the study sample for future research.  
Arguments about the generalizability of study results are not well-formed 
until the relevant characteristics of the target population are explicitly stated (i.e., 
patient characteristics are designated or interference patterns are specified or the 
types of therapy defined). This is analogous to the estimation of controlled direct 
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effects; such direct effects are not well-defined until the researcher specifies that the 
estimator is the direct effect not through M, where M is some possible mediator.33  
Finally, distinguishing internal and external threats to validity is useful for 
determining which parameters in the study sample or target population are 
estimable. When collider stratification bias due to selection is present in a study, it 
may threaten causal inference being made for any population,34 even the study 
sample, and preclude attempts to generalize results to either the source population 
or any specified target population (associational estimate is biased for the causal 
effect in the study sample; generalizability is irrelevant). In contrast, if a study can 
be determined to be free of selection bias (and confounding) (associational estimate 
is an unbiased estimate of the causal effect in the study sample) and differences in 
average treatment effects attributed to nonrandom sampling of the study 
population, methods exist to generalize results to a the target population 
(contingent on all assumptions outlined above).2,35 Standardizing effect estimates to 
the appropriate target population will improve their utility to clinicians and public 
health practitioners, and better inform implementation of interventions in target 
populations. 
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Table 1. Data from a hypothetical target population (𝑁=50,000) and nonrandom 
study sample (𝑛=1,000) 
𝑍1 𝑍1 𝐴 𝑌 N (target) n 
(sample) 
Scaled IP 
sampling 
weighta 
Weighted 
sample 
0 0 0 0 15,023 68 4.239 288.2 
0 0 0 1 1807 11 4.239 46.6 
0 0 1 0 16,046 75 4.239 317.9 
0 0 1 1 1,035 6 4.239 25.4 
0 1 0 0 2,954 85 0.712 60.5 
0 1 0 1 1,285 35 0.712 24.9 
0 1 1 0 3,221 91 0.712 64.7 
0 1 1 1 1,078 29 0.712 20.6 
1 0 0 0 2,087 88 0.506 44.5 
1 0 0 1 914 28 0.506 14.2 
1 0 1 0 2,285 88 0.506 44.5 
1 0 1 1 787 36 0.506 18.2 
1 1 0 0 360 84 0.082 6.9 
1 1 0 1 378 97 0.082 8.0 
1 1 1 0 517 125 0.082 10.3 
1 1 1 1 223 54 0.082 4.4 
a Scaled inverse probability of sampling weight 
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Table 2. Summary data from a hypothetical target population (𝑁=50,000) and crude 
and inverse probability of sampling weighted nonrandom study sample (𝑛=1,000) 
Target population  Study sample  Weighted sample 
 Y=0 Y=1 Risk   Y=0 Y=1 Risk   Y=0 Y=1 Risk 
X=0 20,424 4,384 0.177  X=0 325 171 0.345  X=0 400 94 0.190 
X=1 22,069 3,123 0.124  X=1 379 125 0.248  X=1 437 69 0.136 
RD: -0.053    RD: -0.097    RD: -0.054   
RR: 0.702    RR: 0.719    RR: 0.716   
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Figure 1. Possible choices for the target population of interest 
 
 
 
 
 
 
 
The target population (large, light gray square) can relate to the study sample 
(small, dark gray circle) in multiple ways. (a) The study sample is a random sample 
from the target population. (b) The study sample is not a random sample from the 
target population. (c) The target population is external to the study sample. The 
target population can be described by either a census of the target population or a 
random sample of the target population (small, dark gray square). In situation (b) or 
(c), the study sample can be thought of as a random sample from a larger super-
population (larger, light gray circle) that differs from the target population; if the 
analysis does not standardize or transport results to the target population, inference 
is restricted to this super-population.  
1a: 1b: 1c: 
